[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 16, 1994

β-Agonist Use and Death from Asthma

Author Affiliations

Wellington School of Medicine Wellington, New Zealand

JAMA. 1994;271(11):822-823. doi:10.1001/jama.1994.03510350029021
Abstract

To the Editor.  —We read with interest the meta-analysis of Mullen et al1 of case-control studies of β-agonists and asthma death, and we are in agreement with its methodology and general conclusions. The meta-analysis shows that the results of Spitzer et al2 are significantly different from those reported by all other researchers, whereas the finding of our New Zealand case-control studies3-5 are consistent with those of other researchers.6,7 Mullen et al1 suggest that the findings of Spitzer et al2 may be different because they focused on an older age-group. An alternative explanation is that the findings of Spitzer et al2 are inconsistent because of methodological flaws in the study.Their study was based on patients who had received 10 or more prescriptions for one or more asthma drugs during a 10-year period, and patient medication was then assessed for the previous 12 months

First Page Preview View Large
First page PDF preview
First page PDF preview
×